COVID-19 tracker: Moderna’s vaccine for 6 to 11 age group elicited strong immune response in trialnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Generic Paxlovid will be sold to poor countries for less than $25news2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: US supports Pfizer vaccines being used in North Koreanews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: FDA endorses Pfizer booster for 5 to 11 age groupnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Lilly, AZ and Pfizer treatments could run short, official saysnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Usage of Pfizer, Merck’s antivirals soared over the past monthnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: White House cancels AstraZeneca’s vaccine contractnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: AZ clinches booster nod as 3rd Pfizer dose charts topline win in kidsnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: FDA panel to review Moderna, Pfizer vaccines for young children next monthnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Moderna seeks dismissal in Alnylam patent casenews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
